Get the Stockscreener App
1.415
8.71%
-0.135
After Hours:
1.41
-0.005
-0.35%
Erasca Inc stock is traded at $1.415, with a volume of 1.02M.
It is down -8.71% in the last 24 hours and up +11.42% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.55
Open:
$1.52
24h Volume:
1.02M
Relative Volume:
0.79
Market Cap:
$400.85M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.7256
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-17.25%
1M Performance:
+11.42%
6M Performance:
-25.13%
1Y Performance:
-55.08%
1-Day Range:
$1.3907
$1.54
1-Week Range:
$1.3907
$1.81
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.415 | 439.10M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors - Insider Monkey
How to track smart money flows in Erasca Inc.Chart Signal and Short-Term Forecast Tracker - Newser
Why Erasca Inc. stock attracts strong analyst attentionROI Focused Watchlist with Trade Confidence - Newser
How to build a dashboard for Erasca Inc. stockMulti-Bagger Detection with Trend Tools - Newser
What are analysts’ price targets for Erasca Inc. in the next 12 monthsWealth Building Growth Plan For Consistent Profits - jammulinksnews.com
Is Erasca Inc. stock ready for a breakoutAI-Based Stock Behavior Forecast Engine - Newser
Can Erasca Inc. Overcome Bearish SentimentSecure Capital Picks With Upside Potential Tracked - beatles.ru
When is the best time to exit Erasca Inc.Buy Zone Strategy with Pattern Recognition - Newser
Can momentum traders help lift Erasca Inc.Long Term Stock Growth Plan Suggestions - Newser
Erasca Inc. Building a Base Near SupportIntraday Trend Analysis for Fast Gains Released - metal.it
Can Erasca Inc. Outperform Peers After Recent PullbackEntry Plan for Oversold Reversal Stocks Released - metal.it
Why Erasca Inc. stock is on top investor watchlistsLow Risk High Confidence Watchlist Builder - Newser
Is Erasca Inc. a growth stock or a value stockFinancial News Data Feed With Proven Results - jammulinksnews.com
What markets is Erasca Inc. expanding into Is VATE stock a good long term investment optionBreakthrough financial growth - jammulinksnews.com
Why is Erasca Inc. stock attracting strong analyst attentionGet timely alerts on market opportunities - jammulinksnews.com
What catalysts could drive Erasca Inc. stock higher in 2025Daily Trading Outlook With Proven Results - jammulinksnews.com
How strong is Erasca Inc. company’s balance sheetAchieve rapid capital gains with smart investing - jammulinksnews.com
What makes Erasca Inc. stock price move sharplyInvest smarter with advanced market data - jammulinksnews.com
How does Erasca Inc. compare to its industry peersUnlock powerful portfolio optimization tools - jammulinksnews.com
Published on: 2025-07-27 19:36:39 - jammulinksnews.com
How Resilient Is Erasca Inc. Stock During Economic DownturnsDaily Trade Opportunity - Newser
Key External Factors That Drive Erasca Inc. Stock Price MovementsReal Time Alert Service - Newser
How Erasca Inc. stock performs during market volatilityRisk Limited High Gain Trades - Newser
What drives Erasca Inc. stock priceTremendous growth opportunities - PrintWeekIndia
What analysts say about Erasca Inc. stockOverwhelming financial success - PrintWeekIndia
Is Erasca Inc. stock a growth or value playUnprecedented market success - jammulinksnews.com
How high can Erasca Inc. stock price go in 2025Exceptional risk-adjusted gains - jammulinksnews.com
Erasca Inc. Stock Analysis and ForecastRapid growth trajectories - Autocar Professional
Is Erasca Inc. a good long term investmentMarket-crushing stock picks - PrintWeekIndia
ERAS’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):